Multiple Sclerosis Clinical Trial

Clinical Trial Finder Multiple Sclerosis Trials

An Extension of the TG1101-RMS201 Trial

See Locations Near You

Summary

This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects currently enrolled in TG1101-RMS201 trial
Subjects who have completed three infusions of ublituximab (at Day 1, Day 15, and Week24, as specified in the TG1101-RMS201 protocol) and have completed the scheduled assessments up to the final 48-week visit

Exclusion Criteria:

Subjects who discontinued ublituximab treatment or withdrew consent from the TG1101- RMS201 study during the 48-week evaluation period
Subjects who have started any other immunomodulating or disease modifying therapy after completion of the TG1101-RMS201 trial
Pregnant or nursing mothers

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

48

Study ID:

NCT03381170

Recruitment Status:

Completed

Sponsor:

TG Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 8 Locations for this study

See Locations Near You

TG Therapeutics Investigational Trial Site
Pasadena California, 91105, United States
TG Therapeutics Investigational Trial Site
Aurora Colorado, 80045, United States
TG Therapeutics Investigational Trial Site
Lexington Kentucky, 40513, United States
TG Therapeutics Investigational Trial Site
Columbus Ohio, 43210, United States
TG Therapeutics Investigational Trial Site
Westerville Ohio, 43081, United States
TG Therapeutics Investigational Trial Site
Knoxville Tennessee, 37922, United States
TG Therapeutics Investigational Trial Site
Round Rock Texas, 78681, United States
TG Therapeutics Investigational Trial Site
San Antonio Texas, 78258, United States
Load More

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

48

Study ID:

NCT03381170

Recruitment Status:

Completed

Sponsor:


TG Therapeutics, Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider